Magma Partners invests in Fluap's pre-seed round

We’re excited to back Augusto Pimenta and the Fluap team as they build a neutral, plug-and-play digital infrastructure that brings order, traceability, and intelligence to the care system.

Across Latin America, care often breaks between prescription and treatment. Doctors rarely know whether patients follow through, patients face friction at the last mile, and pharma teams access and patient-support programs with delayed, manual reporting. Without timely data, it’s hard to measure impact and even harder to improve outcomes. The industry ultimately pays the price through higher costs and poorer treatment adherence.

Much of this breakdown happens outside the traditional commercial channel. Samples, access programs, donations, and near-expiry inventory often sit in a black box, a multi-billion-dollar blind spot across Latin America. Visibility drops, compliance weakens, waste rises, and the system loses the feedback loop it needs to improve access. Fluap is built for that blind spot.

Fluap helps orchestrate how pharmaceutical assets and benefits move through the healthcare supply chain, standardizing and capturing real-world events from manufacturer to patient in one clear, checkable history. This makes it easier to confirm where a sample came from, that it meets required rules, and that it truly reached the intended person without relying on assumptions.

Just as important, Fluap generates primary, consented real-world data grounded in what actually occurs across the access and adherence journey, enabling real-time monitoring and optimization.

We invested because Fluap is addressing a core infrastructure gap. When non-direct pharmaceutical flows become auditable and real-time, the entire ecosystem benefits: less waste, stronger compliance and traceability, better resource allocation, and an intelligence layer that strengthens the path to improved patient outcomes.

“We are excited to back Augusto and the Fluap team as they build the digital infrastructure for Brazil’s health segment. The company is well-positioned to solve long-standing inefficiencies in the pharmaceutical ecosystem, as the team has lived these challenges firsthand. Their early POCs with top 10 industry players by revenue in a multibillion-dollar market provide strong early validation for the thesis, highlighting a clear need for a solution like Fluap.” Matheus Cerqueira, Analyst at Magma Partners.

We’re proud to support Augusto and the Fluap team as they build the rails for a more transparent, efficient, and human healthcare experience.

“Care only transforms when it flows. Today, much of that flow is lost in manual processes, physical benefits, and systems that can’t see what happens in the real world. Fluap exists to connect these gaps and build the rails for a healthcare experience that is transparent, data-driven, and truly patient-centered. We’re proud to have Magma by our side as we build this new layer of infrastructure for Brazil and Latin America”. Augusto Pimenta, Founder and CEO at Fluap.